Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dewi Vernerey

Showing results (71-80 of 155) with videos related to

Pageof 16
Sort By:
European Journal of Cancer (Oxford, England : 1990)|April 30, 2022
Impact of trough concentrations of regorafenib and its major metabolites M-2 and M-5 on overall survival of chemorefractory metastatic colorectal cancer patients: Results from a multicentre GERCOR TEXCAN phase II studyBenoit Rousseau, Arezki K Boukerma, Julie Henriques, et al.
Journal for Immunotherapy of Cancer|May 19, 2025
Interplay between sarcopenia, GDF-15, and the efficacy of nivolumab plus ipilimumab in patients with mismatch repair deficient metastatic colorectal cancer: final survival analysis of the phase II GERCOR NIPICOL studyLeonard Depotte, Paula Nay, Christophe Borg, et al.
International Journal of Cancer|July 30, 2016
Prognostic value of baseline seric Syndecan-1 in initially unresectable metastatic colorectal cancer patients: a simple biological scoreMarine Jary, Thierry Lecomte, Olivier Bouché, et al.
Journal of the American Society of Nephrology : JASN|January 4, 2015
Subclinical Rejection Phenotypes at 1 Year Post-Transplant and Outcome of Kidney AllograftsAlexandre Loupy, Dewi Vernerey, Claire Tinel, et al.
Journal for Immunotherapy of Cancer|November 5, 2020
RECIST and iRECIST criteria for the evaluation of nivolumab plus ipilimumab in patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the GERCOR NIPICOL phase II studyRomain Cohen, Jaafar Bennouna, Aurélia Meurisse, et al.
Clinical Colorectal Cancer|March 26, 2022
Sequential Treatment With Trifluridine/Tipiracil and Regorafenib in Refractory Metastatic Colorectal Cancer Patients: An AGEO Prospective "Real-World Study"Clélia Coutzac, Isabelle Trouilloud, Pascal Artru, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|January 5, 2011
Significance of C4d Banff scores in early protocol biopsies of kidney transplant recipients with preformed donor-specific antibodies (DSA)A Loupy, G S Hill, C Suberbielle, et al.
Journal of the American Society of Nephrology : JASN|April 5, 2014
Molecular microscope strategy to improve risk stratification in early antibody-mediated kidney allograft rejectionAlexandre Loupy, Carmen Lefaucheur, Dewi Vernerey, et al.
European Journal of Cancer (Oxford, England : 1990)|October 5, 2023
Time to recurrence and its relation to survival after recurrence in patients resected for stage III colon cancerCosimo Rasola, Pierre Laurent-Puig, Thierry André, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 14, 2020
Prognostic Value of Tumor Deposits for Disease-Free Survival in Patients With Stage III Colon Cancer: A Post Hoc Analysis of the IDEA France Phase III Trial (PRODIGE-GERCOR)Jean-François Delattre, Romain Cohen, Julie Henriques, et al.
Pageof 16

Showing results (71-80 of 155) with videos related to

Sort By:
Pageof 16
European Journal of Cancer (Oxford, England : 1990)|April 30, 2022
Impact of trough concentrations of regorafenib and its major metabolites M-2 and M-5 on overall survival of chemorefractory metastatic colorectal cancer patients: Results from a multicentre GERCOR TEXCAN phase II studyBenoit Rousseau, Arezki K Boukerma, Julie Henriques, et al.
Journal for Immunotherapy of Cancer|May 19, 2025
Interplay between sarcopenia, GDF-15, and the efficacy of nivolumab plus ipilimumab in patients with mismatch repair deficient metastatic colorectal cancer: final survival analysis of the phase II GERCOR NIPICOL studyLeonard Depotte, Paula Nay, Christophe Borg, et al.
International Journal of Cancer|July 30, 2016
Prognostic value of baseline seric Syndecan-1 in initially unresectable metastatic colorectal cancer patients: a simple biological scoreMarine Jary, Thierry Lecomte, Olivier Bouché, et al.
Journal of the American Society of Nephrology : JASN|January 4, 2015
Subclinical Rejection Phenotypes at 1 Year Post-Transplant and Outcome of Kidney AllograftsAlexandre Loupy, Dewi Vernerey, Claire Tinel, et al.
Journal for Immunotherapy of Cancer|November 5, 2020
RECIST and iRECIST criteria for the evaluation of nivolumab plus ipilimumab in patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the GERCOR NIPICOL phase II studyRomain Cohen, Jaafar Bennouna, Aurélia Meurisse, et al.
Clinical Colorectal Cancer|March 26, 2022
Sequential Treatment With Trifluridine/Tipiracil and Regorafenib in Refractory Metastatic Colorectal Cancer Patients: An AGEO Prospective "Real-World Study"Clélia Coutzac, Isabelle Trouilloud, Pascal Artru, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|January 5, 2011
Significance of C4d Banff scores in early protocol biopsies of kidney transplant recipients with preformed donor-specific antibodies (DSA)A Loupy, G S Hill, C Suberbielle, et al.
Journal of the American Society of Nephrology : JASN|April 5, 2014
Molecular microscope strategy to improve risk stratification in early antibody-mediated kidney allograft rejectionAlexandre Loupy, Carmen Lefaucheur, Dewi Vernerey, et al.
European Journal of Cancer (Oxford, England : 1990)|October 5, 2023
Time to recurrence and its relation to survival after recurrence in patients resected for stage III colon cancerCosimo Rasola, Pierre Laurent-Puig, Thierry André, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 14, 2020
Prognostic Value of Tumor Deposits for Disease-Free Survival in Patients With Stage III Colon Cancer: A Post Hoc Analysis of the IDEA France Phase III Trial (PRODIGE-GERCOR)Jean-François Delattre, Romain Cohen, Julie Henriques, et al.
Pageof 16